|
Laboratory Staff
Curriculum Vita
|
|
|
Curriculum Vita
 Harry Pothoulakis, MD
Professor of Medicine
GENERAL INFORMATION
Prepared: March, 2006
Name: Charalabos Pothoulakis, M.D.
Office Address:
Beth Israel Deaconess Medical Center, East Campus
Gastroenterology Division, Dana 601
330 Brookline Avenue, Boston MA 02215
E-Mail: cpothoul@bidmc.harvard.edu
FAX: 617-667-2767
Place of Birth: Athens, Greece
Education
1975 M.D., Aristotelian University of Thessaloniki Medical School, Thessaloniki, Greece
Postdoctoral Training:
1977-81 Internship and Residency, AHEPA General Hospital, Aristotelian University Medical School, Thessaloniki, Greece
1982-84 Research Fellow in Gastroenterology, Boston University School of Medicine, Boston MA
Academic Appointments:
1983-84 Research Instructor of Medicine and Biochemistry
Boston University School of Medicine, Boston, MA
1985-92 Research Assistant Professor of Medicine and Biochemistry,
Boston University School of Medicine, Boston, MA.
1993-95 Research Associate Professor of Medicine and Biochemistry,
Boston University School of Medicine, Boston MA
1996-99 Assistant Professor of Medicine, Harvard Medical School
2000- Associate Professor of Medicine, Harvard Medical School
2005- Professor of Medicine, Harvard Medical School
Hospital or Affiliated Institution Appointments:
1975-77 Medical Corps, Greek Army.
1994-95 Faculty Member, Neuroscience Program, Department of Pharmacology, Boston University School of Medicine, Boston MA.
2002- Director, Gastrointestinal Neuropeptide Center, Gastroenterology Division, Beth Israel Deaconess Medical Center
2005- Senior Research Associate, Division of Pediatric Gastroenterology and Nutrition Massachusetts General Hospital
Major Committee Assignments:
Regional:
1989 Faculty Resource for Students, Member, Boston University School of Medicine.
1998 Member, Examinations Committee for Ph.D. thesis of Leena Kudchadker Singh. "Effects of stress, corticotropin-releasing hormone and urocortin on rat skin mast cell degranulation and vascular permeability". Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston MA.
1999-03 Member, Review Committee for Pilot Feasibility Study Grants. Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital, Harvard Medical School, Boston MA.
1999-04 Member, Review Committee for Pilot Feasibility Project Grants, Clinical Nutrition Research Center at Harvard, Harvard Medical School, Boston MA.
2002 Chairman, Abstract Review Award Committee, Fourth Annual Research Symposium, New England Hellenic Medical And Dental Society, Boston, MA.
2003 Member, Examinations Committee for Ph.D. thesis of Kristiana Kandere-Grzybowska, "Neuroinflammatory activation of mast cells and differential release of IL-6".
Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston MA.
National and International:
1993 Review Committee, Medical Research Project Grant Applications, Ad Hoc Reviewer, Medical Research Council, London UK.
1994-95 Member, Committee for Improvement of Medical Education in Greece, Ministry of Health, Athens, Greece.
1996 Member, Abstract Review Committee, Digestive Disease Week, American Gastroenterological Association.
1997 Chairman, Abstract Review Committee, Digestive Disease Week, American Gastroenterological Association.
1997 Member, Review Committee, NIH/NIDDK Program Project Grant "Intestinal Immune System in Host Environment Interactions", University of San Diego.
1998 Member, Abstract Review Committee for the "12th International Symposium on Regulatory Peptides". University of Michigan Medical School.
1998 Member, Review Committee, Merit Award Applications,
Department of Veterans Affairs, VA Palo Alto Health Care System.
1997 Member, Review Committee, NIH/NIDDK Special Emphasis Panel, Silvio O. Conte Digestive Diseases Research Core Centers.
1997 Member, Review Committee, NIH/NIDDK Special Emphasis Panel, "Integrative Approaches to the Study of Motility of the Gastrointestinal Tract.
2000-01 Ad hoc Member, NIH/NIDDK, General Medicine-2 Study Section
2001–05 Permanent Member, NIH/NIDDK General Medicine –2 Study Section
2001- Reviewer, Inflammatory Bowel Disease Grants, The Eli and Edythe L. Broad Foundation.
2002- Councilor, Section of Hormones, Transmitters, Growth Factors and Their Receptors, American Gastroenterological Association
2002 Ad Hoc Reviewer, "Establishment of Postgraduate Programs in Medical Education". Hellenic Ministry of Education, and European Common Market, Athens, Greece.
2002 Ad Hoc Reviewer, "Establishment of Undergraduate Programs in Medical Education". Hellenic Ministry of Education, and European Common Market, Athens, Greece.
1997 Member, Abstract Review Committee, Digestive Disease Week 2003, American Gastroenterological Association.
2003 Organizer and moderator, "New paradigms in motility and intestinal Inflammation", Digestive Disease Week 2003, American Gastroenterological Association, Orlando, FL.
1997 Chairman, Abstract Review Committee, Digestive Disease Week 2004, American Gastroenterological Association
2004- Councilor, Immunology, Microbiology, Inflammatory Bowel Disease Section, American Gastroenterological Association
2004 Organizer and Session Moderator, "Hormones and Signaling Pathways Regulate Mucosal Inflammation" and "Microbial-Induced Inflammation and Immunity", Digestive Disease Week 2004, American Gastroenterological Association, New Orleans, MI.
2004-05 Reviewer, Crohn’s and Colitis Foundation of America
2004 Session Organizer, European Society of Clinical Investigation, 39th Annual Scientific Meeting, April 2005, Athens, Greece
2004 Review Committee Organizer for IMIBD "Probiotics in intestinal inflammation, immunity and IBD" and "Epithelial - cell-microbial interactions in inflammation and immunity. Microbial-induced mucosal inflammation and immunity" Sessions for Digestive Disease Week 2005, Chicago, IL.
2006 Ad Hoc Reviewer, Special Emphasis Panel, NIH, NIDDK
Professional Societies:
1989-90 New England Hellenic Medical and Dental Society, Treasurer
1989- American Society of Microbiology, Member
1990-91 New England Hellenic Medical and Dental Society, Secretary.
1990- International Society of Toxicology, Member
1990- Society of Microbial Ecology and Disease (SOMED), Member
1991-92 New England Hellenic Medical and Dental Society, President
1991- Hellenic Society of Gastroenterology, Member
1991- American Gastroenterological Association, Member
1991- Gastroenterology Research Group (GRG), Member
1997- American Physiologic Society, Member
Editorial Boards:
1991- Ad Hoc Reviewer, Gastroenterology
1993- Ad Hoc reviewer, Infection and Immunity
1993- Ad Hoc Reviewer, American Journal of Physiology
1994 Ad Hoc Reviewer, The Journal of Gerontology
1998 Ad Hoc Reviewer, Urology
1998 Ad Hoc Reviewer, Journal of Pharmacology and Experimental Therapeutics
1998- Ad Hoc Reviewer, Inflammatory Bowel Diseases
1999 Ad Hoc Reviewer, Anaerobe
1999 Ad Hoc Reviewer, Clinical Immunology
1999 Ad Hoc Reviewer, Canadian Journal of Microbiology
1999 Ad Hoc Reviewer, Life Sciences
2000 Ad Hoc Reviewer, Nature Medicine
2000 Ad Hoc Reviewer, Journal of Clinical Investigation
1999- Member of the Editorial Board, Hellenic Journal of Gastroenterology
1999-04 Member of the Editorial Board, Gastroenterology
2000-03 Member of the Editorial Board, American Journal of Physiology
2002 Ad Hoc Reviewer, Cancer Research
2002- Ad Hoc Reviewer, Brain Research
2003 Ad Hoc Reviewer, Scandinavian Journal of Gastroenterology
2003 Ad Hoc Reviewer, Biochemica Biophysica Acta
2003- Ad Hoc Reviewer, Oncogene
2003 Ad Hoc Reviewer, Journal of Neurochemistry
2004 Ad Hoc Reviewer, Journal of Molecular Biology
2005 Ad Hoc Reviewer, Am Journal of Pathology
2006 Ad Hoc Reviewer, Expert Opinion on Investigational Drugs
2006 Ad Hoc Reviewer, Obesity Research
Awards and Honors:
1982-84 Scholarship from the Aristotelian University Medical School, Thessaloniki, Greece.
1985 M.D. Honors Dissertation: Aristotelian University Medical School, Thessaloniki, Greece, No. 1310.
1986-90 American Gastroenterological Association Industry Award
2002 Janssen Award in Basic Research in Gastrointestinal Motility
2004 Nominee for "Excellence in Mentoring Award" at Harvard Medical School.
1997 Award for "Excellence in Research in Gastroenterology" presented by the Hellenic Society in Gastroenterology during the 24th Hellenic Congress in Gastroenterology, Athens, Greece.
RESEARCH, TEACHING AND CLINICAL CONTRIBUTIONS
Over the past few years our understanding of the pathophysiology of enterotoxin actions has evolved from a classic cell-oriented model to an integrated model incorporating neuronal and immune mediators in the lamina propria. According to the classic model, the pathogenesis of cholera toxin-mediated diarrhea requires binding of the toxin to a brush border receptor and increases in the level of enterocyte cyclic AMP, followed by intestinal chloride and water secretion via the paracellular pathway. An expanded model to explain cholera toxin diarrhea was advanced in the early 90’s by Lundgren and his associates based on in vivo experiments and use of nerve blockers. These studies showed that a rate-limiting step in cholera diarrhea was regulation by intestinal neurons This new paradigm of toxin-mediated intestinal secretion holds that the nervous system amplifies signals originating in the lumen when toxins stimulate villus cell. My laboratory has incorporated this new model of toxin action into our studies of Clostridium difficile enterotoxin, the causative agent of antibiotic-associated colitis. In contrast to cholera toxin, which causes a watery diarrhea without inflammatory cells, C. difficile enterotoxin diarrhea is accompanied by considerable tissue necrosis and an intense acute neutrophilic infiltrate. My laboratory showed for the first time that inflammatory diarrhea caused by C. difficile enterotoxin is controlled by sensory neurons containing the neuropeptides substance P and CGRP. Two other neuropeptides peptides, corticotropin-releasing hormone and neurotensin are also involved in intestinal inflammation and secretion caused by this enterotoxin opening up the possibility for extensive communication between sensory neurons, neuroendocrine cells and enteric nerves in the pathophysiology of inflammatory diarrhea. Our studies also demonstrated that the mechanism by which some of these peptides mediate intestinal inflammation and secretion in the intestine is by interacting with specific receptors on epithelial cells as well as on immune and inflammatory cells of the intestinal lamina propria, including macrophages and mast cells. This notion has been recently extended in the pathophysiology of human disease as indicated by results from experiments using native human colon. These studies were the first in the field to directly link the neuropeptides substance P and neurotensin with secretory responses in human colon. Recent exciting results also indicate that the appetite suppressor hormone leptin is also a proinflammatory peptide involved in enterotoxin-mediated diarrhea and inflammation
This work is highly significant to the pathophysiology and treatment of intestinal secretion and inflammation and provided important rationale and experimental evidence for clinical studies examining the effects of neuropeptide receptor inhibitors in inflammatory bowel disease and irritable bowel syndrome currently underway in the US and Europe. Moreover, the American Gastroenterological Association recognized this work by the highly prestigious "Janssen Award in Basic Research in Gastrointestinal Motility" awarded to me this year. Based on the funding success and the pathophysiologic importance of these projects I have also established this year a "Gastrointestinal Neuropeptide Center" in the Division of Gastroenterology at Beth Israel Deaconess Medical Center that involves a multi-disciplinary approach to study neuropeptide function in the GI tract.
One of my goals is to define the molecular mechanism by which the peptides substance P, neurotensin, and CRH stimulate cells in the intestine and identify the specific signaling pathways that are activated in response to these peptides at the colonocyte level. My laboratory also showed a dramatic early increase in the expression of substance P, neurotensin, CRH, and leptin receptors in the intestine during the course C. difficile toxin - mediated intestinal inflammation. NIH-funded studies underway in my laboratory are examining the mechanisms of upregulation of the substance P receptor gene on intestinal epithelial cells and macrophages during intestinal inflammation. Specifically we are studying the role of proinflammatory cytokines in activation of lamina propria macrophages and how such activation leads to upregulation of substance P receptors.
My research group is also studying the pathways by which communication between the central nervous system and the endocrine and immune systems control colonic function. In a series of papers we have shown that acute immobilization stress in rats causes colonic mucin and prostaglandin secretion and colonic mast cell activation, and that the neuropeptides CRF and neurotensin participate in these colonic responses. We are currently examining the mechanisms of neurotensin and CRH receptor regulation in animal models of stress and in the colon of patients with irritable bowel syndrome. Since neurotensin stimulates mucin release in native human colonocytes and human colonic cell lines, we are also studying in these cells the signal transduction pathways leading to mucin release following neurotensin exposure.
Research Funding Information:
Past:
1982-84 Scholarship from the Aristotelian University Medical School, Thessaloniki, Greece.
1986-90 American Gastroenterological Association, PI, "Mechanism of action of Clostridium difficile toxins A and B".
1990-92 KOS Pharmaceuticals, Inc. PI, "Role of intestinal mast cells in intestinal inflammation"
1992-94 Crohn’s and Colitis Foundation of America, Inc. PI, "Mechanism of receptor mediated intestinal inflammation and damage".
1994-96 Crohn’s and Colitis Foundation of America, Inc., Research Fellowship Award, Mentee: Ignazio Castagliuolo, M.D.), "Role of substance P in intestinal inflammation and diarrhea".
1995-00 Sanofi Research, Inc., PI, "Role of neurotensin on Irritable Bowel Syndrome (SR-48692)".
1997-99 Crohn’s and Colitis Foundation of America, Inc. PI, "Role of the hypothalamic-pituitary-adrenal axis and Corticotropin-releasing factor in intestinal inflammation".
1997-98 Crohn’s and Colitis Foundation of America, Inc., Career Development Award, Mentee: Ignazio Castagliuolo, M.D.), "Role of neurotensin in intestinal inflammation".
2001 AstraZeneka Inc. PI, "Mechanisms of Mucosa Barrier Modulation".
1994-02 Synsorb Biotech., Inc. PI, "Inhibition of Clostridium difficile toxin A and B effects with SYNSORBs".
2001-02 Clinical Nutrition Research Center at Harvard (NIH-supported), PI, "Leptin and Mechanisms of Intestinal Inflammation"
1992-03 Biocodex, Inc. Co-PI, "Intestinal mechanisms of Saccharomyces boulardii".
2004 Cambridge Antibody Technology, Cambridge, UK, Co-PI, "Inhibition of Clostridium difficile toxin-mediated enterocolitis using anti-toxin antibodies"
2002-04 Crohn’s and Colitis Foundation of America, PI, "Leptin and Mechanisms of Intestinal Inflammation"
2002-04 Crohn’s and Colitis Foundation of America, Inc., Research Fellowship Award, Mentee: Simos Simeonidis, Ph.D.,"The Role of the NF-kB/IkB pathway in substance P-induced inflammation in the colon".
1999-05 National Institutes of Health NIDDK (DK 33506), Program Project, "Barrier Function of the GI tract in Health and Disease", Project 4: "Role of CRH in intestinal inflammation", PI
2002-05 ActivBiotics, Inc. PI, "Effect of RIFALAZIL in Clostridium difficile - Mediated Cecitis in Hamsters"
2004-05 Salix Pharmaceuticals, Inc. Raleigh, North Carolina, USA. Co-PI, "Effect of rifaximin in primary and secondary prevention of Clostridium difficile associated diarrhea and colitis in hamsters"
Current:
1995-10 National Institutes of Health NIDDK (DK 33506), Program Project, Program Director, "Barrier Function of the GI tract in Health and Disease", Project 1: "Role of CRH in intestinal inflammation", PI, Administrative Core, PI, Project 5: Mechanisms for the intestinal probiotic effects of S. boulardii, Co-Investigator
1994-08 National Institutes of Health NIDDK (RO1 DK47343), PI, "Role of substance P in intestinal inflammation".
2002-07 National Institutes of Health RO1-DK-60729, PI, "Mechanisms of colonic responses to neurotensin"
2006-11 National Institutes of Health 1 RO-1 DK072471, PI, "Toll-like receptors and intestinal inflammation"
1984-07 National Institutes of Health NIDDK (R37 DK034583), Co-PI, "Intestinal Mechanisms of C. difficile toxins".
2001-06 National Institutes of Health NIDDK (RO1 DK 58858), Co-investigator, "Leukocyte recruitment in IBD".
2004-09 National Institutes of Health NIDDK, Co-investigator, "Immune Response to Clostridium difficile"
Current Mentor Funding:
2004-09 National Institutes of Health NIDDK (KO1DK064920), Mentee: Dezheng Zhao, Ph.D.,"Role of ghrelin in intestinal inflammation"
2004-07 Crohn’s and Colitis Foundation of America, Inc., Research Fellowship Award, Mentee: Sang Hoon Rhee, Ph.D., "The role of Toll-like receptor 5-mediated signaling pathways in Inflammatory Bowel Disease"
2005-06 AGA/Centocor International Research Fellowship in GI Inflammation and Immunology, Foundation for Digestive Health and Nutrition, Mentee: Alan Moss, M.D. "Corticotropin-releasing hormone and IBD"
2006-08 Crohn’s and Colitis Foundation of America, Inc., Research Fellowship Award Mentee: HoonWei Koon, Ph.D. "Mechanisms of the healing effects of substance P in intestinal inflammation"
2005-06 National Institutes of Health T32 DK007477 – 21, Training in Pediatric Gastroenterology and Nutrition (PI: Wayne Lencer), Mentee: Kara J Gross, M.D. "Role of Melanin-concentrating hormone in adipose tissue and intestinal inflammation"
Report Of Teaching:
As a full time basic researcher, I am not involved in clinical teaching of medical students. I organize nearly all the teaching programs in basic science in the Division of Gastroenterology, and these programs are offered to all medical students who rotate through our division. These include weekly research seminars, journal club, invited speakers programs, and basic science workshops as detailed below. I devote approximately 10-15% of my total effort to teaching, laboratory instructing, and mentoring of medical students and fellows.
Local Contributions:
1996-2003 Section of Gastroenterology, Beth Israel Deaconess Medical Center, Research in Progress Seminars Organizer and Presenter, Twice a month, approximately 10 outside speakers per year, 2-4 medical students, 20-30 gastroenterology fellows, postgraduate doctors, and staff, 10 hours per year
1996-2003 Section of Gastroenterology, Beth Israel Deaconess Medical Center, Basic Science Journal Club Organizer and Presenter, Once a month, 2-4 medical students, 20-30 gastroenterology fellows, postgraduate doctors and staff, 6 hours per year
1996-2003 Section of Gastroenterology, Beth Israel Deaconess Medical Center, Clinical Sciences Journal Club, Organizer, Once a month, 2-4 medical students, 20-30 gastroenterology fellows, postgraduate doctors and staff, 6 hours per year
1991-95 Section of Gastroenterology, Boston University School of Medicine, Research in Progress Seminars Organizer and Presenter, 1-2 medical students, 10-15 gastroenterology fellows, postgraduate doctors, and staff, 10 hours per year
1991-95 Section of Gastroenterology, Boston University School of Medicine, Research Seminars Organizer, Approximately 10 outside speakers per year, 1-2 medical students, 10-15 gastroenterology fellows, postgraduate doctors and staff, 10 hours per year
1991-95 Section of Gastroenterology, Boston University School of Medicine, Basic Science Journal Club, Organizer and Presenter, 1-2 medical students, 10-15 gastroenterology fellows, postgraduate doctors and staff, 10 hours per year
1995 "Gastroenterology Update 1995", Boston University School of Medicine. Lecturer, 45-50 medical doctors from Germany. 8 hours
1995 Enteric Biology Course, Harvard Medical School. Lecturer. 8-10 medical students, 40-60 residents, and postdoctoral fellows. 8 hours.
1995-1997 "Gastroenterology Update 1995, 1996 & 1997". Boston University School of Medicine. Lecturer. 45-50 medical doctors from Germany per course. 24 hours.
1997-2001 "Gastroenterology Update 1997, 1998, 1999, & 2001", Beth Israel Deaconess Medical Center. Chairman and Lecturer. 45-50 medical doctors from Greece per course. 24 hours.
1999 Graduate Program in Biochemistry and Pharmacology. Tufts University School of Medicine, Boston MA., Lecturer. 2-4 medical students, 15-20 graduate and postgraduate students. 8 hours.
2000 Graduate Program in Pharmacology. Boston University School of Medicine, Lecturer. 2-4 medical students, 15-20 graduate and postgraduate students. 8 hours.
2001 Graduate Program in Biochemistry and Pharmacology, Tufts University School of Medicine, Lecturer. 2-4 medical students 25-30 graduate and postgraduate students. 8 hours.
Local Invited Teaching Presentations:
1989 "Research Seminar Series". Section of Gastroenterology, St. Elizabeth’s Hospital, Boston, MA. Lecturer. 1-2 medical students, 25-30 residents, fellows, postgraduate students and staff. 8 hours
1990 "Gastroenterology Seminar Series", Section of Gastroenterology, Boston VA Medical Center, Lecturer. 1-2 medical students, 25-30 residents, fellows, postgraduate students and staff. 8 hours
1994 "Research Seminar Series". Department of Gastroenterology and Center for Inflammatory Bowel Disease, Massachusetts General Hospital. 1-2 medical students. Lecturer. 25-30 residents, fellows, postgraduate students and staff. 8 hours
1995 "Research Seminar Series. Section of Immunology, Beth Israel Hospital. Lecturer. 1-2 medical students, 15-20 fellows and postgraduate students. 8 hours
1997 Gastroenterology Research Seminar Series, Harvard Digestive Disease Center. Lecturer. 2-4 medical students, 15-20 fellows and postgraduate students. 8 hours
1997 7th Annual Workshop in "Intestinal Epithelium Immune and Inflammatory Responses". The Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital. Lecturer. 4-8 medical students, 70-80 senior and junior investigators, fellows, and postgraduate students. 8 hours
1998 Harvard Digestive Disease Center and Program in Pediatric Gastroenterology and Nutrition, Lecturer. 2-4 medical students, senior and junior investigators, fellows, postgraduate students and staff. 25-30
1998 8th Annual Symposium in "Intestinal Epithelium Immune and Inflammatory Responses". Center for the Study of Inflammatory Bowel Disease. Massachusetts General Hospital. Lecturer. 4-8 medical students, 70-80 senior and junior investigators, fellows, graduate and postgraduate students. 8 hours
1999 Mucosal Immunology Group, Program in Pediatric Gastroenterology and Nutrition, Massachusetts General Hospital and Children’s Hospital. Lecturer. 2-4 medical students, 25-30 senior and junior investigators, fellows, postgraduate students and staff. 8 hours
2000 Program in Biomolecular Pharmacology. Boston University School of Medicine. Lecturer. 2-4 medical students, 30-40 senior and junior investigators, fellows, and postgraduate students. 8 hours
2001 Harvard Digestive Disease Center and Program in Pediatric Gastroenterology and Nutrition. Lecturer. 2-4 medical students, 25-30 senior and junior investigators, fellows, postgraduate students and staff. 8 hours
2001 11th Annual Workshop on: NF-kB in Host Defense: Genetics, Biochemistry and Function. Center for the Study of Inflammatory Bowel Diseases Massachusetts General Hospital. Lecturer and Session Moderator. 4-8 medical students, 70-80 senior and junior investigators, fellows, graduate and postgraduate students. 10 hours
2002 "Program in Biomolecular Pharmacology", Boston University School of Medicine. Lecturer. 2-4 medical students, 30-40 senior and junior investigators, fellows, and postgraduate students. 8 hours
2004 "The Center for Faculty Development Ph.D.’s Subcommittee", Harvard Medical School Panel Discussant: The HMS Promotion Process Demystified for the Investigator. 20-30 senior and junior investigators, fellows and postgraduate students. 4 hours.
2005 Division of Gastroenterology Research Seminar Series, Bringham and Women’s Hospital, Harvard Medical School Lecturer. 1-2 medical students, 25-30 residents, fellows, postgraduate students and staff. 8 hours.
2005 Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Research Surgical Seminars. Lecturer. 2-4 medical students, 25-30 Senior and junior investigators, fellows, postgraduate students and staff. 8 hours
2005 "The Center for Faculty Development Ph.D.’s Subcommittee", Harvard Medical School Panel Discussant: HMS Promotion Seminars. 20-30 senior and junior investigators, fellows and postgraduate students. 4 hours.
2005 Harvard School of Public Health, Department of Nutrition, Research Seminar Series. Lecturer. 2-4 medical students, 25-30 Senior and junior investigators, fellows, postgraduate students and staff. 8 hours
2006 Boston Nutrition Seminars, Harvard Clinical Nutrition Research Center, The Boston Obesity Nutrition Research Center. Lecturer.
Advisory and supervisory responsibilities, Boston University School of Medicine
1985-1995 Supervision and Research Training of Gastroenterology Fellows, approximately 350 hours per year, 1 -3 Fellows per year.
1985-95 Supervision and Research Training of Graduate Students, approximately 350 hours per year, 1-2 graduate students in laboratory per year
1990-95 Medical Student Advisor, 45 hours per year, Beth Israel Deaconess Medical Center
1996- Supervision and Research Training of Gastroenterology Fellows, approximately 350 hours per year, 1-3 Fellows per year
1996- Supervision and Research Training of Undergraduate and Graduate Students approximately, 350 hours per year, 2-3 students per year
2002- M.D., Ph.D. Thesis advisor for Morris Tansky. Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine. 45 hours per year.
Teaching leadership role
1997 Gastroenterology Update 1997, Course Co-Director. Organizer of 2 postgraduate medical courses presented by the Division of, Gastroenterology at Beth Israel Deaconess Medical Center to approximately 110 gastroenterologists from Greece. Organize program, select and recruit speakers, edit syllabus, chair meeting.
1998 Gastroenterology Update 1998, Course Co-Director, Athens and Thessaloniki Greece. Organizer of a postgraduate medical course presented by members of the Division of Gastroenterology at Beth Israel Deaconess Medical Center, to approximately 500 gastroenterologists and Internists in Greece. Organize program, select and recruit speakers, edit syllabus, chair meeting.
1999 Gastroenterology Update 1999, Course Co-Director. Organizer of a postgraduate medical course presented by the Division of Gastroenterology at Beth Israel Deaconess Medical Center to approximately 40 gastroenterologists from Greece. Organize program, select and recruit speakers, edit syllabus, chair meeting
2001 Gastroenterology Update 2001, Course Co-Director. Organizer of a postgraduate medical course presented by the Division of Gastroenterology at Beth Israel Deaconess Medical Center to approximately 40 gastroenterologists from Greece. Organize program, select and recruit speakers, edit syllabus, chair meeting.
2005 39th Annual Scientific Meeting, European Society of Clinical Investigation, Athens Greece. Session Organizer. Organize program, select and recruit speakers, review abstract and chair the session.
Advisees or Trainees
Years, Name, Present Position
1985-90 George Triadafilopoulos, M.D. Professor in Medicine, Stanford University
1987-91 Ning Zhao, MS, Research Associate, AstraZeneca R&D,
1992-99 Ignazio Castagliuolo, MD, Assistant Professor, University of Padua, Italy
1993-96 Fotini Vavva, Graduate Student, Department of Biochemistry, Boston University School of Medicine
1993-96 Joanne Linevski, M.D., Assistant Professor in Medicine, University of Pennsylvania,
1994-97 Bosheng Qiu, MD, Research Associate, Columbia University
1995-98 Andrew Keates, Ph.D., Assistant Professor in Medicine, HMS
1996-98 Martin Riegler, MD, Professor in Surgery University of Vienna, Austria
1997-00 Asia Pasha, Graduate Student, Department of Biochemistry, Cornell University
1997 Constantine Mimidis, MD, Assistant Professor, University of Thrace, Greece
1997-99 Leila Valenick, Ph.D. Program in Molecular Biology, Princeton University
1997-01 Sabina Kuhnt-Moore, New York Medical College, Medical Student
1997-01 Jennifer Liu, University of Massachusetts Medical School, Medical Student
1997-02 Chi Chi Wang, MS, Research Associate, Millennium Pharmaceuticals
1998-02 Michel Warny, Ph.D., Program Leader, Acambis Inc.
1998-00 Sam Aboudola, M.D., Fellow in Gastroenterology, Yale University,
1999-02 Dezheng Zhao, Ph.D., Instructor in Medicine, HMS
1999-03 Ming Chen, Ph.D., Research Associate, MIT
1999-02 Sigfus Nikulasson, M.D., Assistant Professor in Pathology, Medical School, University of Iceland, Reykjavik
2000-02 Amir Qamar, M.D., Fellow in Pathology, University of Chicago
2000-04 Stavros Sougioultzis, M.D., Assistant Professor in Medicine, University of Athens Medical School
2000-02 Fabio Cataldi, M.D., Group Leader, Novartis Pharmaceuticals
2001-03 Michael Wlk, University of Vienna Medical School
2001- Morris Tansky, M.D., Ph.D Program, Boston University School of Medicine
2001-04 Pauline Anton, Ph.D, Lecturer in Physiology and Pharmacology, Agricultural Institute of Beauvais, France
2001-02 Simos Simeonidis, Ph.D., Instructor in Medicine, HMS, Program Leader, Novartis Pharmaceuticals
2002 Johanna Husmark, Ph.D., Research Associate, Astrazeneca R& D
2003-04 Sang Hoon Rhee, Research Associate, HMS
2003 Efi Kokkotou, M.D., Instructor in Medicine, HMS
2005-06 Alan Moss, M.D., Fellow in Gastroenterology, HMS
2005-07 Kara Gross, MD, Fellow in Pediatric Gastroenterology, HMS
Regional, National, and International Contributions
1990 Research Seminar, Symposium on Clostridium difficile Associated Colitis. Organized by Biocodex, Inc., Paris, France
1994 State of the Art Lecture, 5th International Symposium in Intestinal Inflammation. University of Zagreb, Zagreb, Republic of Croatia.
1994 Research Seminar, Hippokration Hospital, University of Athens Medical School, Section of Neuroendocrinology, Athens, Greece.
1994 Research Seminar, University of Athens Medical School, Athens, Greece.
1994 Research Seminar, Genetics Institute, Inc. Cambridge MA.
1994 Research Seminar, T Cell Sciences, Inc. Boston MA.
1994 Research Seminar, PARK-DAVIS, Inc. Ann Arbor MI.
1994 Research Seminar, Division of Gastroenterology and Department of Internal Medicine, The University of Michigan Medical Center, Ann Arbor, MI
1994 Research Seminar, "Interactions Between Genetics and Microbiology in Inflammatory Bowel Disease" Organized by the CCFA, AGA and NIH., Hilton Head, SC.
1995 State of the Art lecture, "Symposium on Inflammatory Disorders of the Intestine", Department of General Surgery, Clinic of Surgery, University of Vienna, Vienna, Austria.
1995 Research Seminar, Workshop "Recent Advances in Clostridium difficile and its Toxins", 4th Congress of the France Society of Microbiology, Tours, France.
1995. State of the Art Lecture, Symposium. "Updates on Clostridium difficile", Organized by Biocodex, Inc. Paris, France.
1995 State of the Art Lecture, Annual American Gastroenterological Association Meeting, San Diego, CA.
1994 Chairperson of the session "Pathogenesis of Gastrointestinal Infections", Annual American Gastroenterological Association Meeting, San Diego, CA.
1995 Postgraduate Course, Annual Hellenic Gastroenterological Association Congress, Thessaloniki, Greece.
1995 State of the Art Lecture, Annual Hellenic Gastroenterological Association Congress, Thessaloniki, Greece.
1996 State of the Art Lecture, "Medicine in the 21st Century: Medical and Technological Update", Hellenic-American Medical Society, Athens Greece.
1994 State of the Art Lecture "New Approaches to Pharmacotherapy for Hepatic and Gastrointestinal Ulcerative and Inflammatory Disorders Symposium", Sperlonga, Italy.
1996 State of the Art Lecture, 16th Hellenic Armed Forces Health Services Conference, Thessaloniki, Greece.
1996 Research Seminar, Lilly Research Laboratories. Indianapolis, Indiana
1994 State of the Art Lecture, 4th International Congress on Immune Consequences of Trauma, Shock, and Sepsis: Mechanisms and Therapeutic Approaches. Munich, Germany.
1997 Co-Chairperson of the session "Pathogenesis of Gastrointestinal Infections". Annual American Gastroenterological Association Meeting, Washington, DC.
1997 Invited Speaker, AGA Research Symposium in Hormone Receptors and Gut Inflammation, Annual American Gastroenterological Association Meeting, Washington, D.C.
1997 Research Seminar, Pulmonary and Critical Care Section, Yale University, New Haven, CT.
1994 Research Seminar, Keystone Symposia, Enteric Nervous System. Santa Fe, New Mexico.
1998 Chairman and Speaker, State of the Art Lecture, Gastroenterology Update 1998, Athens, Greece
1998 Co-Chairperson of the Session "Microbial Pathogenesis", Annual American Gastroenterological Association Meeting, New Orleans, LA.
1998 Workshop in "Motility of the Digestive Tract: Research Directions and Priorities". The National Institute of Diabetes Digestive and Kidney Diseases, Bethesda, MD
1998 State of the Art Lecture, Fourth International Symposium on Brain-Gut Interactions, La Jolla, CA.
1998 Research Seminar, Division of Digestive Diseases, University of Cincinnati,, Cincinnati, OH
1998 State of the Art Lecture, 18th Annual Congress of the Hellenic Society of Gastroenterology, Athens, Greece.
1998 Research Seminar, Hellenic Pasteur Institute, Athens, Greece.
1995 Research Seminar, Fifth Workshop In "Epithelial Transport and Barrier Function: Pathomechanisms in GI disorders". Organized by the Intestinal Mucosa Function Group of the German Society of Gastroenterology and the Universities of Frankfurt, Munster, and Berlin, Berlin, Germany.
1999 Research Seminar, Creative BioMolecules, Inc., Hopkinton, MA.
1999 Research Seminar, Department of Physiology, University of Massachusetts, Worcester MA.
2000 Presenter and Chairman "Brain-Gut 2000", Organized by the Functional Brain-Gut Research Group and The Research Group of the International Brain Gut Society, Toulouse, France.
2001 Keynote Speaker, Symposium, "Advances in Gastroenterology in the Beginning of the 21st Century" Aristotelian University of Thessaloniki Medical School, Thessaloniki, Greece
2001 Research Seminar, Department of Biology, Aristotelian University of Thessaloniki Medical School, Thessaloniki, Greece.
2001 Chairperson of the Microbial Pathogenesis AGA Research Forum, Annual American Gastroenterological Association Meeting, Atlanta GA
2001 Research Seminar, The R. W. Johnson Pharmaceutical Research, Spring House, PA.
2001 Presenter and Chairman, "Mucosal Defense Mechanisms of Intestinal Diseases", Organized by AstraZeneca and McMaster University, Gothenburg, Sweden.
2001 Research Seminar, Department of Gastroenterology, University of Michigan, Ann Arbor, MI
2001 Research Seminar, "Fall 2001 Seminar Series", Department of Anatomy and Neurobiology,, University of Vermont, Burlington, VT.
2002 Research Seminar, Division of Gastroenterology, Yale University School of Medicine, West Haven, CT
2002 State of the Art Lecture. Annual American Gastroenterological Association Meeting, Washington, D.C.
2003 "The Stow Conference on Digestive Diseases Course". The University of Vermont, College of Medicine, Stowe, VT.
2003 Senior Discussant, Third Annual Workshop on Immunogenetic Mechanisms of Intestinal Inflammation: Role of the Epithelium. University of Virginia Health Sciences Center, Charlottesville, Virginia
2003 Named Lecture, Medical Grand Rounds, "34th Annual Chaikin Lecture in Gastroenterology", New York Medical College, Department of Medicine. Valhalla NY.
2003 Research Seminar, Gastroenterology Division. New York Medical College, Valhalla NY.
2003 Research Seminar, Interdisciplinary Seminar Series Organized by the Department of Physiology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma.
2003 Research Seminar, Mucosa Barrier Function Group, AstraZeneka Pharmaceuticals,, Gothenburg, Sweden
2003 Research Seminar, Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA.
2003 State of the Art Lecture, 11th International Conference on Ulcer Research. Dubrovnik, Kroatia
2003 Department of Medicine Lecture Series. University of Massachusetts Medical Center Worcester, MA.
1995 Department of Pathology Research Seminar Series. Boston University School of Medicine Boston, MA.
2004 Invited Speaker, First International Clostridium difficile Symposium, Kranjska Gora, Slovenia
2004 Digestive Disease Center and Division of Gastroenterology Seminar Series, Washington University School of Medicine, St. Louis, Missouri
2004 Invited Lecturer, Academy of Athens Foundation of Biomedical Research, Athens, Greece.
2004 Meet-the-Professor/Meet-the-Investigator Speaker, Annual American Gastroenterological Association Meeting New Orleans, LI.
2004 Invited Lecture, Research Seminar, Regeneron Pharmaceuticals, Inc., Terrytown, NY.
2004 Research Seminar, Mucosa Barrier Function and Molecular Gastrointestinal Pharmacology, Group, AstraZeneka Pharmaceuticals,, Gothenburg, Sweden
2004 Key Note Speaker, 24th Hellenic Congress of Gastroenterology, Athens, Greece.
2004 Invited Speaker, Research Seminar, ActivBiotics Inc., Lexington, MA.
1995 Invited Speaker, "Tachykinins 2005"., Breckenridge, CO.
2004 Invited Speaker and Session Organizer, 39th Annual Meeting of the, European Society of Clinical Investigation. Athens, Greece.
2005 Grand Rounds, Department of Surgery, University of San Francisco, San Francisco, CA.
2005 Invited Speaker, AGA Research Symposium in "G protein coupled receptors and signaling", Annual American Gastroenterological Association Meeting, Chicago, IL.
2005, Chairperson of AGA Research Forum "Role of inflammatory peptides in colitis", Sponsored by Hormones, Transmitters, Growth Factors and Their Receptors Section, Annual American Gastroenterological Association Meeting, Chicago, IL
2005 Medical Grand Rounds, Department of Pediatrics, Agia Sophia Hospital University of Athens Medical School, Athens, Greece
2005 Medical Grand Rounds, Department of Medicine and Microbiology, Genimatas General Hospital, Athens Greece
2004 GI Grand Rounds, Gastroenterology Division, University of Texas Medical Center at Galveston Galveston, TX
2006 Research Seminar, Gastroenterology Division, University of Texas Medical Center at Galveston Galveston, TX
BIBLIOGRAPHY
Original Articles:
1. Wedel N, Toselli P, Pothoulakis C, Farris B, Oliver P, Franzblau C, LaMont JT. Ultrastructural effects of Clostridium difficile toxin B on smooth muscle cells and fibroblasts. Exp Cell Res 1983; 148:413-422.
2. Pothoulakis C, Barone LM, Ely R, Faris B, Clark ME, Franzblau C, LaMont JT. Purification and properties of Clostridium difficile cytotoxin B. J Biol Chem 1986; 261:1316-21.
3. Pothoulakis C, Triadafilopoulos G, Clark M, Franzblau C, LaMont JT: Effects of Clostridium difficile toxin B on macromolecular synthesis in human lung fibroblasts and cecal explants. Gastroenterology 1986; 93:1147-53.
4. Triadafilopoulos G, Pothoulakis C, O'Brien M, LaMont JT: Differential effects of Clostridium difficile toxins A and B on rabbit ileum. Gastroenterology 1987;93:273-79.
5. Pothoulakis C, Sullivan R, Melnic DA, Triadafilopoulos G, Gadenne AS, T Meshulam, LaMont JT. Clostridium difficile toxin A stimulates intracellular calcium release and chemotactic response in human granulocytes. J Clin Invest 1988;81:1741-45.
6. Hecht G, Pothoulakis C, LaMont JT, Madara J. Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers. J Clin Invest 1988;82:1516-24.
7. Gilbert RJ, Triadafilopoulos G, Pothoulakis C, Giampaolo C, LaMont JT. Effect of purified Clostridium difficile toxins on intestinal smooth muscle. I. Toxin A. Am J Physiol 1989;256:G759-G766.
8. Gilbert RJ, Pothoulakis C, Triadafilopoulos G, Giampaolo C, LaMont JT. Effect of purified Clostridium difficile toxins on intestinal smooth muscle. II. Toxin B. Am J Physiol 1989; 256:G767-G772.
9. Triadafilopoulos G, Pothoulakis C, Weiss R, Giampaolo C, LaMont JT. Comparative study of Clostridium difficile toxin A and cholera toxin in rabbit ileum. Role of prostaglandins and leukotrienes. Gastroenterology 1989;97:1186-92.
10. Miller PD, Pothoulakis C, Baeker TR, LaMont JT, Rothstein TL. Macrophage-dependent stimulation cell- depleted spleen cells by Clostridium difficile toxin A and calcium ionophore. Cell Immunol 1990; 126:155-163
11. Moore R, Pothoulakis C, LaMont JT, Carlson S, Madara JL. Clostridium difficile toxin A increases intestinal permeability and induces Cl- secretion. Am J Physiol 1990;259:G165-G172.
12. Leung DYM, Kelly CP, Boguniewicz M, Pothoulakis C, LaMont JT, Flores A. Treatment with intravenous gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991;118:633-7.
13. Pothoulakis C, LaMont JT, Eglow RL, Gao N, Rubins JB, Theoharides TC, Dickey BF. Characterization of rabbit ileal receptors for Clostridium difficile toxin A. Evidence for a receptor-coupled G-protein. J Clin Invest 1991; 88:119-125.
14. Triadafilopoulos G, Shah MH, Pothoulakis C. The chemotactic response of human granulocytes to Clostridium difficile toxin A is age-dependent. Am J Gastroenterol 1991; 86:1461-65.
15. Kelly CP, Pothoulakis C, Orellana J, LaMont JT. Human colonic aspirates containing Immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A receptor binding. Gastroenterology 1992;102:35- 40.
16. Hecht G, Koutsouris A, Pothoulakis C, LaMont JT, Madara JL. Clostridium difficile toxin B disrupts the barrier function of T84 monolayers. Gastroenterology 1992;102:416-423.
17. Eglow R, Pothoulakis C, Itzkowitz S, Israel EJ, O'Keane CJ, Gong D, Gao N, Xu YL, Walker WA, LaMont JT. Diminished Clostridium difficile toxin. A sensitivity in newborn rabbit is associated with decreased toxin A receptor. J Clin Invest 1992;90:822-29.
18. Pothoulakis C, Kelly CP, Joshi MA, Gao N, Castagliuolo I, O'Keane CJ, LaMont JT. Saccharomyces boulardii inhibits Clostridium difficile toxin A receptor binding and enterotoxic effect in rat ileum. Gastroenterology 1993;104:1108-1115.
19. Malecka-Panas E, Triadafilopoulos G, Tsukamoto H, Howitt G, Pothoulakis C, LaMont T. Clostridium difficile toxin A stimulates enzyme secretion from isolated rat pancreatic acini. Mater Med Pol 1993; 25:127-31.
20. Pothoulakis C, Karmeli F, Kelly CP, Eliakim R, Joshi MA, O'Keane CJ, Castagliuolo I, LaMont JT, Rachmilewitz D. Ketotifen inhibits toxin A - induced enteriis in rat ileum. Gastroenterology 1993;105:701-707.
21. Beubler E, Schirgi-Degen A, Pabst M, Pothoulakis C, LaMont JT. Effects of purified Clostridium difficile toxin A on fluid secretion in the small intestine of the rat in vivo. Natural Toxins 1993; 1:369-375.
22. Pothoulakis C, Castagliuolo I, LaMont JT, Jaffer A, O'Keane JC, Snider M, Leeman SE. CP-96,345, a substance P antagonist, inhibits rat intestinal responses to toxin A but not cholera toxin. Proc Natl Acad Sci (USA) 1994; 91:947-51.
23. Kelly CP, Becker SD, Linevsky JK, Joshi MA, O'Keane JK, Dickey BF, LaMont JT, Pothoulakis C. Neutrophil recruitment in Clostridium difficile toxin A enteritis. J Clin Invest 1994; 93:1257-1265.
24. Castagliuolo I, LaMont JT, Letourneau R, Kelly CP, O'Keane JC, Jaffer A, Theoharides TC, PothoulakisC. Neuronal involvement in the intestinal effects of Clostridium difficile toxin A and Vibrio cholera enterotoxin. Gastroenterology 1994;107:657-65.
25. Kurose I, Pothoulakis C, LaMont JT, Anderson DC, Paulson JC, Miyasaka M, Wolf R, Granger N. Clostridium difficile toxin A-induced microvascular dysfunction. J Clin Invest 1994; 94:1919-26.
26. Kelly CP, Keates S, Siegenberg D, Linevsky JK, Pothoulakis C, Brady HR. IL-8 secretion and neutrophil activation by colonic epithelial cells in vitro. Am J Physiol 1994;267:G991-G997.
27. Gilbert JR, Pothoulakis C, LaMont JT, Yakubovich M. Clostridium difficile toxin B activates a calcium influx pathway which is required for actin disassembly during cytotoxicity. Am J Physiol 1995;268:G487- G495.
28. Riegler M, Sedivy R, Pothoulakis C, Hamilton G, Zacheri J, Biscof G, Cosetini E, Feil W, Schiessel R, LaMont JT, Wenzl E. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest 1995;95:2004-01.
29. Dillon ST, Rubin E, Yakubovich M, Pothoulakis C, LaMont JT, Feig LA, Gilbert RJ. Involvement of ras- related Rho proteins in the mechanisms of action of Clostridium difficile toxin A and toxin B. Infect Immun 1995;63:1421-26.
30. Burakoff R, Zhao L, Celifarco A, Rose K, Donovan V, Pothoulakis C, Percy WH: Effect of purified toxin A from C. difficile on the rabbit distal colon. Gastroenterology 1995;109:348-54.
31. Kindon H, Pothoulakis C, Thim L, Lynch-Devaney K, Podolsky DK. Trefoil peptides protect intestinal epithelial monolayer/barrier function: cooperative interaction with mucin glycoprotein. Gastroenterology 1995;109:516-523.
32. Kelly CP, Pothoulakis C, Vavva F, Castagliuolo I, Bostwick E, O’Keane JC, Keates S, LaMont JT. Anti- Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob Agents Chemother 1996;40:373-379.
33. Pothoulakis C, Galili U, Shen C, Castagliuolo C, Kelly CP, Nikulasson S, Dudeja P, Brasitus TA, LaMont JT. Human anti-Gal binds to the same receptor and mimics the effects of C. difficile toxin A in rat colon. Gastroenterology 1996;110:1704-1712.
34. Castagliuolo I, LaMont JT, Qiu B, Pothoulakis C. A receptor decoy inhibits the enterotoxic effects of Clostridium difficile toxin A in rat ileum. Gastroenterology 1996;111:433-438.
35. Qiu B, Pothoulakis C, Castagliuolo I, Nikulasson Z, LaMont JT. Nitric Oxide inhibits intestinal secretion by Clostridium difficile toxin A, but not Vibrio cholerae enterotoxin in rat ileum. Gastroenterology 1996;111:409-418.
36. Pothoulakis C, Gilbert RJ, Cladaras C, Castagliuolo I, Semenza G, Hitti Y, Montcrief JS, Linevsky J, Kelly CP, Nikulasson S, Himanshu PD, Wilkins TD, LaMont JT: Rabbit sucrase-isomaltase contains a functional receptor for Clostridium difficile toxin A. J Clin Invest, 98:641-649, 1996.
37. Castagliuolo I, Leeman SE, Bartolak-Suki E, Nikulasson S, Qiu BS, Carraway RE, Pothoulakis C. A neurotensin antagonist, SR 48692 inhibits colonic responses to immobilization stress in rats. Proc Natl Acad Sci (USA) 1996;93:12611-12615.
38. Castagliuolo C, LaMont JT, B. Qiu, Flemming SM, Bhaskar KR, Nikulasson ST, Kornetsky C, Pothoulakis C. Acute stress causes mucin release from rat colon: Role of corticotropin releasing factor and mast cells. Am J Physiol 1996;271: G884-G892.
39. Castagliuolo I, LaMont JT, Nikulasson ST, Pothoulakis C. Purified Saccharomyces boulardii protease inhibits C. difficile toxin A effects in rat ileum. Infect Immun 1996;64:5225-5232.
40. Kelly CP, Chetham S, Keates S, Bostwick EF, Roush AM, Castagliuolo I, LaMont JT, Pothoulakis C. Survival of anti-C. difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrobial Agents and Chemotherapy 1997 41: 236-241.
41. Castagliuolo I, Keates AC, Qiu B, Kelly CP, Nikulasson S, Leeman SE, Pothoulakis C. Increased substance P responses in dorsal root ganglia and intestinal macrophages during Clostridium difficile toxin A enteritis in rats. Proc Natl Acad Sci (USA) 1997;94:4788-4793.
42. Castagliuolo C, Kelly CP, Qiu B, Nikulasson ST, LaMont JT, Pothoulakis C. IL-11 inhibits Clostridium difficile toxin A enterotoxicity in rat ileum. Am J Physiol 1997;273:G333-G341.
43. Salcedo J, Keates S, Pothoulakis C, Warny M, Castagliuolo I, LaMont JT, Kelly CP. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut 1997;41:366-370.
44. Linevsky JK, Pothoulakis C, Keates S, LaMont JT, Kelly CP. IL-8 release and neutrophil activation by Clostridium difficile toxin A-exposed human monocytes. Am J Physiol 1997;273:G1333-G1340.
45. Riegler M, Sedivy R, Sogukoglu T, Castagliuolo I, Pothoulakis C, Consentini E, Boschof G, Hamilton G, Teleky B, Feil W, LaMont JT, and Wenzl E. Epidermal growth factor attenuates Clostridium difficile toxin A- and B-induced damage of human colonic mucosa in vitro. Am J Physiol 1997;273:G1014-G1022.
46. Keates AC, Castagliuolo I, Qiu B, Nikulasson S, Sengupta A, Pothoulakis C. CGRP upregulation in dorsal root ganglia and ileal mucosa during Clostridium difficile toxin A-induced enteritis. Am J Physiol 1998; 274:G196-G202.
47. Bathia M, Saluja AK, Hofbauer B, Frossard J-L, Lee HS, Castagliuolo I, Wang C-C, Gerard C, Pothoulakis C, Steer ML. Role of substance P and the NK-1 receptor in acute pancreatitis associated with lung injury. Proc. Natl. Acad. Sci (USA) 1998;95:4760-65.
48. Castagliuolo I, Riegler M, Nikulasson S, Lu B, Gerard C, Gerard NP, Pothoulakis C. NK-1 receptor is required in Clostridium difficile - induced enteritis. J. Clin. Invest 1998;101:1547-1550.
49. Wershil B, Castagliuolo I, Pothoulakis C. Mast cell involvement in Clostridium difficile toxin A-induced intestinal fluid secretion and neutrophil recruitment in mice. Gastroenterology 1998;114:956-964.
50. Mun EC, Mayol JM, Riegler M, O’Brian TC, Farokhzad OC, Song JC, Pothoulakis C, Hrnjez BJ, Matthews JB. Levamisol inhibits intestinal Cl- secretion via basolateral K+ channel blockade. Gastroenterology 1998;114:1257-67.
51. Castagliuolo I, Keates AC, Wang C. C., Pasha A, Valenick L, Kelly CP, Nikulasson ST, LaMont JT, Pothoulakis C. Clostridium difficile toxin A stimulates macrophage inflammatory protein-2 production in rat intestinal epithelial cells. J Immunol 1998;160:6039-6045.
52. Pothoulakis C, Castagliuolo I, Leeman SE, Wang C, Li H, Hoffman BJ, Mezey E. Increased substance P receptor expression in intestinal epithelial cells during Clostridium difficile toxin A enteritis in rats. Am J Physiol 1998;275:G68-G75.
53. Castagliuolo I, Wershil BK, Karalis K, Pasha A, Nikulasson ST, Pothoulakis C. Colonic mucin release in response to immobilization stress is mast cell - dependent. Am J Physiol 1998;274:G1094-G1100.
54. Percy WH, Burakoff R, Rose K, Desai HP, Xu YL, Pothoulakis C, Eglow R. In vitro evidence that rabbit distal colonic muscularis mucosae has a Clostridium difficile toxin A receptor. Am J Physiol 1998;275:G402-G409.
55. Choi RS, Riegler M, Pothoulakis C, Kim BS, Mooney D, Vacanti M, Vacanti JP. J. Studies of brush border enzymes, basement membrane components, and electrophysiology of tissue-engineered neointestine. J Pediatr Surg 1998; 33:991-6.
56. Riegler M, Lotz M, Sears C, Pothoulakis C, Castagliuolo I, Wang CC, Sedivy R, Sogukoglu T, Cosentini E, Bischof G, Feil W, Teleky B, Hamilton G, LaMont JT, Wenzl E. Bacteroides fragilis (BFT-2) damages human colonic mucosa in vitro. Gut 1999;44:504-510.
57. Castagliuolo I, Riegler MF, Valenick L, LaMont JT, Pothoulakis C. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxin A and B in human colonic mucosa. Infect Immun 1999;67:302-307.
58. Warny M, Fatimi A, Bostwick EF, Laine DC, Lebel F, LaMont JT, Pothoulakis C, Kelly CP. Bovine immunoglobulin concentrate-Clostridium difficile retains C. difficile toxin neutralizing activity after passage through the human stomach and small intestine. Gut 1999;44:212-217.
59. Qiu B, Pothoulakis C, Castagliuolo I, Nikulasson S., LaMont J.T. Participation of reactive oxygen metabolites in Clostridium difficile Toxin A-Induced Enteritis in Rats. Am J Physiol1999;276:G485-G490.
60. Castagliuolo I, Wang C-C, Valenick L, Pasha A, Nikulasson S, Carraway RE, Pothoulakis C. Neurotensin is a proinflammatory peptide in colonic inflammation. J Clin Invest 1999;103:843-849.
61. Riegler I, Castagliuolo I, So PTC, Lotz M, Wang C, Wlk M, Sogukoglu T, Cosentini E, Bischof G, Hamilton G, Teleky B, Wenzl E, Matthews JB, Pothoulakis C. Effects of substance P on human colonic mucosa in vitro., Am J Physiol 1999;276:G1473-G1483.
62. Riegler M, Castagliuolo I, Wlk M, Pothoulakis C. Substance P evokes a chloride - dependent short-circuit current (Isc) response in rabbit colonic mucosa. Scand J Gastroenterol 1999; 34:1203-1211.
63. Warny M, Keates AC, Keates S, Castagliuolo I, Zacks JF, Aboudola S, Qamar A, Pothoulakis C, LaMont JT, Kelly CP. p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production and enteritis. J Clin Invest 2000;105:1147-1156.
64. He D, Hagen SJ, Pothoulakis C, Chen M, Medina ND, Warny M, LaMont JT. Clostridium difficile toxin A causes early damage to mitochondria and ATP depletion. Gastroenterology 2000;119:139-50
65. Riegler M, Castagliuolo I, Wang C, Wlk M, Sogukoglou T, Wenzl E, Matthews JB, Pothoulakis C. Neurotensin stimulates Cl- secretion in human colonic mucosa in vitro. Gastroenterology 2000;119:248-57.
66. Xia Y, Hu HZ, Liu S, Pothoulakis C, Wood JD. Clostridium difficile toxin A excites enteric neurons and suppresses sympathetic neurotransmission in the guinea pig. Gut 2000;46:481-486.
67. Castagliuolo I, Valenick L, Liu J, Pothoulakis C. EGF receptor transactivation mediates SP-induced mitogenic responses in U-373 MG cells. J. Biol. Chem 2000;275:26545-50.
68. Akbarali HI, Pothoulakis C, Castagliuolo I. Altered ion channel activity in murine colonic smooth muscle myocytes in an experimental colitis model. Biochem Biophys Res Commun 2000;275: 637-642.
69. Castagliuolo I, Karalis K, Valenick L, Pasha A, Nikulasson S, Pothoulakis C. Endogenous corticosteroids modulate Clostridium difficile toxin A – mediated enteritis in rats. Am J Physiol 2001;280: G539-G545.
70. Qamar A, Warny M, Michetti P, Pothoulakis C, JT LaMont, Kelly CP. Saccharomyces boulardii stimulates an intestinal IgA immune response to Clostridium difficile toxin A in mice. Infect Immun, 2001;69: 2762-65.
71. Kirkwood SK, Bunnett NW, Castagliuolo I, Liu B, Gerard N, Zacks J, Pothoulakis C, Grady EF. Deletion of neutral endopeptidase exacerbates intestinal inflammation induced by Clostridium difficile Toxin A. Am J Physiol. 2001;281:G544-G551.
72. Zhao D, Keates A, Kuhnt-Moore S, Moyer MP, Kelly CP, Pothoulakis C. Signal transduction pathways mediating neurotensin-stimulated interleukin-8 expression in human colonocytes J Biol Chem 2001;276:44464-
73. Chen ML, Pothoulakis C, LaMont JT. PKC signaling regulates ZO-1 translocation and increased paracellular flux of T84 colonocytes exposed to Clostridium difficile toxin A. J. Biol. Chem 2002;277:4247-4254.
74. Morteau O, Castagliuolo I, Zacks J, Lu B, Pothoulakis C*, Gerard NP, Gerard C. Genetic deficiency in the chemokine receptor CCR1 protects against Clostridium difficile toxin A enteritis in mice. Gastroenterology, 2002; 122:725-733. * Corresponding Author.
75. Agarwal B, Halmos B, Feoktistov AS, Protiva P, Ramey GR, Pothoulakis C, LaMont JT, Holt PR. Mechanism of lovastatin-induced apoptosis in intestinal epithelial cells. Carcinogenesis, 2002;23:521-528.
76. He D, Sougioultzis S, Hagen S, Liu J, Keates S, Keates AC, Pothoulakis C, LaMont JT. Clostridium difficile toxin A triggers human colonocyte IL-8 release via mitochondrial oxygen radical generation. Gastroenterology, 2002;122:1048-57.
77. Castagliuolo I, Morteau O, Keates AC, Valenick L, C-C Wang, Zacks J, Lu B, Gerard NP, Pothoulakis C. Protective effects of NK-1 receptor during colitis in mice: role of the epidermal growth factor receptor. Br J Pharmacol., 2002;136: 271-279.
78. Wlk M, Karalis K, Wang C-C, Venichaki M, Liu J, Zhao D, Zacks J, Pothoulakis C. Corticotropin- releasing hormone is a proinflammatory peptide in the mouse ileum. Gastroenterology, 2002;123:505-15.
79. Zhao D, Kuhnt-Moore S, Zeng H, Pan A, Wu J, Simeonidis S, Pothoulakis C. Substance P- stimulated interleukin-8 expression in human colonic epithelial cells involves activation of MAP kinases and Rho GTPases. Biochem J, 2002;368:665-72.
80. Mykoniatis A, Anton PP, Wlk M, Wang CC, Ungsunan L, Blueher S, Venihaki M, Simeonidis S, Zacks J, Zhao D, Sougioultzis S, Karalis K, , Mantzoros M, Pothoulakis C. Leptin mediates Clostridium difficile- induced enteritis in mice. Gastroenterology 2003;124:683-91
81. Simeonidis S, Castagliuolo I, Pan A, Leu J, Wang C-C, Mykoniatis A, Pasha A, Valenick L, Sougioultzis S, Zhao D, Pothoulakis C. Regulation of the NK-1 receptor gene expression in human macrophage cells via an NF-kB site on its promoter. Proc Natl Acad Sci (USA), 2003;100:2957-62.
82. Liu TS, Musch MW, Sugi K, Hendrickson B, Pothoulakis C, LaMont JT, Chang EB. Cytoprotective role of heat shock protein 72 against Clostridium difficile toxin A-induced intestinal dysfunction. Am J Physiol (Cell) 2003; 284:C1073-82.
83. Zhao D, Kuhnt-Moore S, Zeng H, Wu JS, Moyer MP, Pothoulakis C. Neurotensin stimulates interleukin-8 expression in human colonic epithelial cells through Rho GTPase-mediated NF-kB pathways. Am J Physiol (Cell) 2003;284:C1397-404.
84. Savidge T, Pan W, Newman P, O’Brien M, Pothoulakis C. Clostridium difficile toxin B is an enterotoxin for human intestine in vivo. Gastroenterology 2003; 125:413-20.
85. Lu L, Baldeon ME, Savidge T, Pothoulakis C, Walker WA. Development of microbial-human enterocyte interaction: cholera toxin. Pediatr Res 2003; 54:212-8.
86. Stucchi AF, Shebani KO, Leeman SE, Wang CC, Reed KL, Fruin AB, Gower AC, McClung JP, Andry CD, O'Brien MJ, Pothoulakis C, Becker JM. A Neurokinin 1 Receptor Antagonist Reduces an Ongoing Ileal Pouch Inflammation, and the Response to a Subsequent Inflammatory Stimulus. Am J Physiol 2003; 285:G1259-67.
87. Rhee SH, Keates AC, Moyer MP, Pothoulakis C. MEK is a key modulator for TLR5-induced IL-8 and MIP3alpha gene expression in non-transformed human colonic epithelial cells. J Biol Chem 2004; 279:25179-88.
88. Anton PM, Gay J, Mykoniatis A, Pan A, O’Brien M, Brown D, Karalis K, Pothoulakis C. Corticotropin- releasing hormone (CRH) requirement in Clostridium difficile toxin A - mediated intestinal inflammation. Proc Natl Acad Sci (USA) 2004; 101: 8503-8508.
89. Anton PM, O’Brien M, Kokkotou E, Einsenstein B, Michaelis A, Rothstein D, Paraschos S, Kelly CP, Pothoulakis C. Rifalazil treats and prevents relapse of Clostridium difficile – associated diarrhea in hamsters. Antimicrob Agents Chemother 2004 48:3975-9.
90. Zhao D, Koon M, Zhan Y, Zeng H, Keates S, Moyer MP, Pothoulakis C. Metalloproteianse-dependent TGFa release mediates neurotensin-stimulated MAP kinase activation in human colonic epithelial cells. J Biol Chem 2004; 279: 43547-43554.
91. Riegler M., Cosentini E., Sedivy R., Sogukoglu T., Prettenhofer M, Bischof G., Pothoulakis C., Wenzl E. Hepatocyte Growth Factor Stimulates Epithelial Restitution in Rabbit Duodenum in vitro. Eur Surg, 2004; 36: 368-376
92. Koon HW, Zhao D, Na X, Moyer MP, Pothoulakis C. Metalloproteinases and transforming growth factor- alpha mediate substance-P induced mitogen-activated protein kinase activation and proliferation in human colonocytes. J Biol Chem 2004; 279:45519-45527.
93. Sougioultzis S, Kyne L, Drudy D, Keates S, Maroo S, Pothoulakis C, Giannasca PJ, Lee CK, Warny M, Monath TP, Kelly CP. Clostridium difficile toxoid vaccine in recurrent C. difficile associated diarrhea. Gastroenterology 2005;128:764-70..
94. Na X, Zhao D, Koon H-W, Kim H, Husmark J, Moyer MP, Pothoulakis C, LaMont JT. Clostridium difficile Toxin B activates the EGF receptor and the ERK/MAP kinase pathway in human colonocytes. Gastroenterology 2005; 128:1002-11.
95. Zhao D, Zhan Y, Zeng H, Koon H-W, Moyer MP, Pothoulakis C. Neurotensin stimulates interleukin-8 expression through modulation of IkBa phosphorylation and p65 transcriptional activity: involvement of protein kinase Ca. Mol Pharmacol 2005; 67:2025-31.
96. Bradesi S, Schwetz I, Ennes HS, Lamy CM, Ohning G, Fanselow M, Pothoulakis C, McRoberts JA, Mayer EA. Repeated exposure to water avoidance stress in rats: A new model for sustained visceral hyperalgesia. Am J Physiol, Gastrointest Liver Physiol. 2005; 289:G42-53.
97. Kim H, Rhee SH, Kokkotou E, Na X, Savidge T, Moyer MP, Pothoulakis C, LaMont JT. Clostridium difficile toxin A regulates inducible COX-2 and PGE2 synthesis in colonocytes via reactive oxygen species and activation of p38 MAP kinase. J. Biol Chem 2005; 280:21237-45.
98. Koon H-W, Zhao D, Zhan Y, Moyer MP, Pothoulakis C. Substance P-stimulated interleukin-8expression in human colonic epithelial cells involves PKCd activation. J Pharmacol Exp Ther 2005; 314:1393-400
99. Rhee SH, Im E, Riegler M, Kokkotou M, O’Brien M, Pothoulakis C. Pathophysiological role of Toll-like receptor 5 engagement by bacterial flagellin in colonic inflammation. Proc Natl Acad Sci (USA), 2005; 102:13610-5
100. Kim H, Kokkotou E, Na X, Rhee SH, Moyer MP, Pothoulakis C, LaMont JT. Clostridium difficile toxin A- induced colonocyte apoptosis involves p53-dependent-p21(WAF1/CIP1) induction via p38 MAPK. Gastroenterology 2005; 129:1875-88.
101. Zhao D, Zhan Y, Zheng H, Moyer MP, Mantzoros C, Pothoulakis C. Ghrelin is upregulated in intestinal inflammation and stimulates NF-kB-dependent interleukin-8 expression in human colonic epithelial cells. J Cell Biochem, In press.
102. Bradesi S, Kokkotou E, Simeonidis S, Patierno S, Ennes HS, Mittal Y, McRoberts JA, Ohning G, Marvizon JC, Sternini C, Pothoulakis C, Mayer EA. The role of neurokinin 1 receptors in the maintenance of visceral hyperalgesia induced by repeated stress in rats. Gastroenterology, In press.
103. Koon H-W, Zhao D, Zhan Y, Rhee SH, Moyer MP, Pothoulakis C. Substance P stimulates cyclooxygenase-2 and prostaglandin E2 expression through JAK-STAT activation in human colonic Epithelial Cells. J Immunol, In Press.
104. Karagiannides I, Kokkotou E, Tansky M, Tchkonia T, Giorgadze N, O’Brien M, Leeman SE, Kirkland JL, Pothoulakis C. Induction of colitis causes inflammatory responses in mesenteric fat tissue: evidence for substance P-mediated pathways in human mesenteric preadipocytes. Proc Natl Acad Sci (USA), In Press.
105. Sougioultzis S, Simeonidis S, Bhaskar RK, Chen X, Anton PM, Keates S, Pothoulakis C, Kelly CP. Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun. In Press. Reviews, Chapters, and
Editorials
1. Pothoulakis C, Triadafilopoulos, LaMont JT. Antibiotic-Associated Colitis. Comprehensive Therapy 1985;11:68-73.
2. Pothoulakis C, Becker SD, LaMont JT. Mechanism of action of Clostridium difficile toxins. In Rambaud J-C, LaMont JT, editors. Proceedings of the Symposium "Clostridium difficile – Associated Intestinal Diseases". Paris: Society of Microbiology and National France Society of Gastroenterology, 1989:54-61.
3. Pothoulakis C, Castagliuolo, I, LaMont JT. Diagnostic tests for Clostridium difficile diarrhea and colitis. Past, present, and future. J Gastroenterol Hepatolol 1993; 8:311-312.
4. Pothoulakis C, Castagliuolo I, Kelly CP, LaMont JT: Clostridium difficile-associated diarrhea and colitis: pathogenesis and therapy. International Journal of Antimicrobial Agents 1993;3:17-32.
5. Pothoulakis C, LaMont JT: Clostridium difficile colitis and Diarrhea. Gastroenterology Clinics of North America 1993;22(3):623-37.
6. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994;330:257-62.
7. Pothoulakis C. Pathogenesis of Clostridium difficile Associated Diarrhoea. Eur J Gastroenterol Hepatol 1996;8:1041-47.
8. Pothoulakis C. Mechanisms of Saccharomyces boulardii on Clostridium difficile infection. In: LaMont JT, Rambaud J-C, editors. Updates in Clostridium difficile. France: Springler-Verlag; 1996. p. 129-139.
9. Pothoulakis C. Clostridium difficile colitis and diarrhea. Proceeding of the 16th Hellenic Armed Forces Health Services Conference, 1996 Oct 9-12; Thessaloniki, Greece. p. 361-371.
10. Pothoulakis C, Castagliuolo I, LaMont JT. Neurons and mast cells modulate secretory and inflammatory responses to enterotoxins. News in Physiological Sciences, 1998; 13:58-63.
11. Pothoulakis C, Castagliuolo I, Leeman SE. Neuroimmune mechanisms of intestinal responses to stress. In: McCann SM, Lipton JM, Sternberg EM, Chrousos GP, Gold PW, Smith CC, editors. Neuroimmunomodulation: Molecular, Integrative Systems, and Clinical Advances. New York, Annals of New York Academy of Sciences1998;840: p. 635-648.
12. Pothoulakis C. Clostridium, Infection and Immunity. In: Delves PJ, Roitt I editors. Encyclopedia of Immunology, Second Edition. London UK: Academic Press Ltd; 1988. p. 576-577
13. Pothoulakis C. New approaches in the treatment of infectious diarrhea. Proceedings of the 18th Annual Congress of the Hellenic Society of Gastroenterology, 1998 Nov 26-28, Athens, Greece. p. 412-417
14. Pothoulakis C. Enterotoxin A of Clostridium difficile and a-Gal Epitopes. In Galili U, Avila C editors. Subcellular Biochemistry. Volume 32: a-Gal and Anti-Gal. New York: Kluwer Academic/Plenum Publishers. 1999. p. 215-227.
15. Pothoulakis C, LaMont JT. Clostridium difficile and its Toxins. The Regulatory Peptide Letter 2000; 8:39-43.
16. Pothoulakis C. Effects of Clostridium difficile toxins on epithelial cell barrier. In: Schulzke J-D, Fromm M, Riecken E-O, Binder HJ editors. Epithelial Transport and Barrier Function: Pathomechanisms in GI Disorders. New York, Annals of New York Academy of Sciences, 2000; 915: 347-356.
17. Pothoulakis C. The role of neuroenteric hormones in intestinal infectious diseases. Current Opinion in Gastroenterology. 2000;16: 536-540.
18. Pothoulakis C, LaMont JT. The Integrated Response of the Intestine to Clostridium difficile Toxins. Theme Article, Am. J. Physiol, 2001;280:G178-G183.
19. Pothoulakis C. Clostridium difficile infection. Participate, A quarterly publication of the International Foundation for Functional Gastrointestinal Disorders, 2001;10:3, P:6-7.
20. Sougioultzis S, Pothoulakis C. Bacterial Infections: small intestine and colon. Current Opinion in Gastroenterology. 2003; 19:23-30.
21. Pothoulakis C, Castagliuolo I. Infectious pathogens and the neuroenteric system. In Bienenstock J, Goetzl E, Blennerhassett M. editors. Anatomic Neuroimmunology. Vol 15 in the Autonomic Neuroscience Series edited by Burnstock G, In Press.
22. Pothoulakis C. Neuroimmune interactions and pathogenesis of intestinal inflammation in infectiousdiseases. In Gail Hecht, editor. Microbial Pathogens and the Intestinal Epithelial Cell. Washington DC: American Society for Microbiology Press, 2003. p. 351-365.
23. Sougioultzis S, Pothoulakis C. Antibiotic-associated diarrhea. In Johnon RL, editor. Encyclopedia of Gastroenterology, First Edition. San Diego CA: Elsevier Academic Press; 2004. p. 89-93
24. Chen M, Pothoulakis C. Bacterial toxins. In Johnon RL, editor Encyclopedia of Gastroenterology, First Edition. San Diego CA: Elsevier Academic Press, 2004. p. 136-140.
25. Zhao D, Pothoulakis C. Rho GTPases as therapeutic targets for the treatment of inflammatory diseases. Expert Opin Ther Targets. 2003; 7:583-92.
26. Savidge TC, Pothoulakis C. (Editors).Microbial Imaging. London UK, Academic Press. In Press.
27. Zhao D, Pothoulakis C. Neurotensin in gastrointestinal motility and inflammation. In Carraway R, Pothoulakis C, Leeman S editors. Neurotensin in health and disease. Regulatory Peptides, 2006, In Press.
28. Zhao D, Pothoulakis C. Neurotensin in regulation of gastrointestinal functions. In Kastin AB, editor Handbook of Biologically Active Peptides. Elsevier Academic Press, 2006 In Press.
29. Pothoulakis C. Clostridium difficile infection. Participate, A quarterly publication of the International Foundation for Functional Gastrointestinal Disorders, May 2006, In Press.
30. Koon Hon-Wei, Pothoulakis C. Immunomodulatory properties of substance P: gastrointestinal system as a model. New York, Annals of New York Academy of Sciences, In Press.
Dissertation or ThesisPothoulakis C. Studies on purification and mechanism of action of Clostridium difficile cytotoxin (Dissertation). Thessaloniki, Greece: Aristotelian University, School of Medicine, 1985. No1310. pp:1-47.
ABSTRACTS NOT YET PUBLISHED AS A FULL PAPER
1. Valenick L, Castagliuolo I, Riegler M, O’Brien TC, Matthews JB, LaMont JT, Pothoulakis C. Human recombinant interleukin-11 protects hamsters and human colonic mucosa from C. difficile toxin A and B effects. Gastroenterology 1998; 114: A1103.
2. Castagliuolo I, Wang C, Previte GJ, Pasha A, Pothoulakis C. IL-1b stimulates release of substance P and neurotensin and increases expression of their receptors on lamina propria macrophages. Gastroenterology 1998; 114: A1133.
3. Castagliuolo I, Lembo A, Pasha A, Pothoulakis C. Increased neurotensin receptor mRNA in colonic mucosa of patients with irritable bowel disease. Gastroenterology 1998; 114: A357.
4. Castagliuolo I., Valenick L, Riegler M, LaMont JT, Pothoulakis C. Oligosaccharides containing sialic acid and N-acetylglucosamine mediate Clostridium difficile toxin B binding and biologic effects in human colonic mucosa. Gastroenterology 1998; 114:A949.
5. Cataldi F, Castagliuolo I, LaMont JT, Keates A, Pothoulakis C. Protective effects of human recombinant osteogenic protein 1 (Bone morphogenic protein-7) in Clostridium difficile toxin A-mediated enteritis and TNBS-induced colitis. Gastroenterology 2000; 118: A322.
6. Riegler MF, Pothoulakis C, Sogukoglou T, Consentini E, Wenzl E. Effects of adenosine receptor antagonists on human colonic mucosa in vitro. Gastroenterology 2001; 120:A531.
7. Ming C, Pothoulakis C, LaMont JT. Clostridium difficile toxin A binds to a receptor in membrane lipid rafts and induces Erk 1/2 phosphorylation. Gastroenterology 2002; 122:A104.
8. Ming C, Pothoulakis C, LaMont JT. Disassembly of actin stress fibers and focal adhesions induced by Clostridium difficile toxin B is mediated by Rho-associated kinase. Gastroenterology 2002; 122:A534.
9. Anton PM, Goldsmith J, Pothoulakis C, Savidge.T. Clostridium difficile toxin A-induced enterotoxicity isdependent on a functional enteroglial cell network in adult transgenic mice. Gastroenterology 2003; 124: A499.
10. Pothoulakis C, Saluja M, Anton P, Pan A, Dawra R, Garg L, Blueher S, Mantzoros C, Saluja AK. Leptin plays an anti-inflammatory role in acute pancreatitis. Gastroenterology 2003; 124:A502.
11. Ming C, Pothoulakis C, LaMont JT. Receptor for activated C kinase (RACK1) mediates protein kinase C (PKC) signaling induced by Clostridium difficile toxin A. Gastroenterology 2003; 124:A482.
12. Simeonidis S., Pan A., Mykoniatis A., Zhao D., Moyer M. P, Pothoulakis C. The role of I-Kappa-B kinases in the substance P – induced inflammation of the GI tract. Gastroenterology 2003; 124:A466.
13. Anton MP, Pan A, Savidge T, Newman P, Simeonidis S, Karalis K, Pothoulakis P. Clostridium difficile toxin A and proinflammatory cytokines stimulate corticotropin-releasing hormone 2 (CRHR2) expression in human colonic epithelial cells. Gastroenterology 2003; 124:A9.
14. Matkowskyj KA, Mulcahy E, Pothoulakis C, Benya RV. Expression of activated NF-kB, galanin, and galanin-1 receptors (G1R) in enteric nerves and colonocytes in murine and human colitis. Gastroenterology 2003; 124:A328.
16. Gay J, O’Brien M, Kokkotou E, Pothoulakis C, Karalis K. Evidence for a role of IL-6 in acute TNBS- induced colitis in mice. Gastroenterology 2004; 126:A143.
17. Kokkotou E, Winter M, Mustafa N, Torres D, O’Brien M, Karalis K, Pothoulakis C. Astressin 2B, a specific CRH receptor type 2 antagonist, diminishes C. difficile toxin A-mediated intestinal secretion and inflammation. Gastroenterology 2005; 128: A-498.
18. Xinhua C, Kokkotou E, Mustafa N, Bhaskar KR, O’Brien M, Pothoulakis C, Kelly CP. Saccharomyces boulardii anti-inflammatory factor inhibits MAPK activation in colonic epithelial cells and protects against Clostridium difficile toxin A-induced enteritis. Gastroenterology 2005; 128:A-450.
19. Kokkotou E, Karagiannides J, Mustafa N, Savidge T, O’Brien M, Kirkland J, Flier J, Maratos-Flier E, Pothoulakis C. Melanin Concentrating Hormone (MCH) links obesity and inflammation. Gastroenterology 2005: 128: A-98.
20. Na X, Zhao D, Kim H, Pothoulakis C, LaMont JT. Involvement of Rho A GTPase and p38 MAP kinase in Clostridium difficile toxin B-mediated interleukin 8 expression in colonic epithelial cells. Gastroenterology 2005; 128: A662.
|
|
